Learning and Testing Sub-groups with Heterogeneous Treatment Effects:A
  Sequence of Two Studies by Ladhania, Rahul et al.
Learning and Testing Sub-groups with
Heterogeneous Treatment Effects:
A Sequence of Two Studies
Rahul Ladhania1 Amelia Haviland2
Neeraj Sood3 Edward Kennedy2 Ateev Mehrotra4
Abstract
There is strong interest in estimating how the magnitude of treatment effects
of an intervention vary across sub-groups of the population of interest. In our
paper, we propose a two-study approach to first propose and then test hetero-
geneous treatment effects. In Study 1, we use a large observational dataset
to learn sub-groups with the most distinctive treatment-outcome relationships
(‘high/low-impact sub-groups’). We adopt a model-based recursive partition-
ing approach to propose the high/low impact sub-groups, and validate them
by using sample-splitting. While the first study rules out noise, there is po-
tential bias in our estimated heterogeneous treatment effects. Study 2 uses
an experimental design, and here we classify our sample units based on sub-
groups learned in Study 1. We then estimate treatment effects within each of
the groups, thereby testing the causal hypotheses proposed in Study 1. Us-
ing patient claims data from the NBER MarketScan database, we apply our ap-
proach to estimate heterogeneous effects of a switch to a high-deductible health
insurance plan on use of outpatient care by patients with a common chronic
condition. We extend the method to non-parametrically learn the sub-groups in
Study 1. We also compare the methods’ performance to other state-of-the-art
methods in the literature that make use only of the Study 2 data.
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Sub-groups with Heterogeneous Treatment Effects
1 Introduction
There is strong interest in estimating how the magnitude of treatment effects of
an intervention vary across different sub-groups of the population of interest.
Specifically, in fields such as health-care (precision medicine, insurance plan de-
sign), there is value in understanding which patient/enrollee sub-groups will be
high (or low) ‘responders’ to a treatment regime(s), and the magnitude of response
therein. In a number of settings, researchers are hobbled by a lack of theory to
a priori determine sub-groups of interest, a problem further aggravated by the
relative high dimensionality of the co-variate space. In the statistical machine
learning literature, recent studies have used a variety of approaches - tree and
forest based methods (Wager and Athey (2018); Athey and Imbens (2016)); family
of representation-learning based algorithms (Shalit et al. (2016)) - to identify het-
erogeneous treatment effect sub-groups. Notably, these studies estimate hetero-
geneity in causal effects after a study with exogenous variation in treatment, i.e.
experimental or observational settings with plausible unconfoundedness. When
the sample size is ‘large’ enough, these estimators have been demonstrated to
be consistent with well-understood asymptotic sampling distributions. These ap-
proaches, however, have limitations when sample size is a concern, which is often
the case in experimental settings which, apart from being expensive (vis-a`-vis
observational settings) are often designed to have sufficient power to capture the
average treatment effect. With a small sample size, lack of power is the key reason
why it becomes difficult to rule out noise as the cause of observed heterogeneity
in treatment effects. By chance alone, there is a high likelihood that some groups
show larger effects, and cross-validation is a common strategy to rule out noise.
Sample-splitting essentially worsens the problem by reducing the effective sam-
ple size available to learn these groups. Moreover, high-dimensional settings only
serve to aggravate this problem.
In our paper, we propose a two-study approach to mitigate this problem. We
learn and test heterogeneous treatment effect sub-groups in a two-study setting.
The first study uses data with endogenous treatment (observational setting with
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potential confounding) to learn and rule out noise as the cause of potential sub-
groups. The second study uses data with exogenous variation in treatment to
test for heterogeneous treatment effects in the proposed sub-groups. In most ap-
plied policy settings, observational data (e.g. patient claims data), while being of
limited use in causal inference due to valid concerns regarding endogeneity, are
large and inexpensive, especially in comparison to experimental data. Our ap-
proach exploits the ‘largeness’ of the observational data to propose and validate
heterogeneous association sub-groups, where the associations are demonstrated
to be persistent, thus not induced by noise. Study 1, thus, is performed in an ob-
servational data setting, where the goal is to generate specific hypotheses about
noise-free sub-groups that may be high/low impact. We define sub-groups based
on a combination of the observed co-variates, and hypothesize them to be high
(or low) impact based on ‘distinctiveness’ of the estimated relationship in the sub-
group between the outcome and treatment variable relative to the relationship in
the pooled population. We do this using a parametric and a non-parametric ap-
proach. In both the approaches, we adopt sample-splitting by randomly splitting
our Study 1 data into training and validation data-sets, where we learn the groups
on the training data-set, while “validating” them on our validation data-set. In the
parametric approach, we learn the sub-groups with distinctive relationships in
Study 1 using a model-based recursive partitioning approach proposed in Seibold
et al. (2016) on our training data-set. To ensure the associations in the sub-
groups we learn are not random noise, we eliminate sub-groups which do not
demonstrate ‘similar’ associations in the training and validation datasets of the
observational data.
In the non-parametric approach, we run ensemble supervised machine learning
methods separately on the treatment and control groups in our training data-set
to estimate the predicted outcomes based on their co-variates (clinical and de-
mographic features). We define the “treatment-control difference” for each of the
units in our training sample as the difference between the observed outcomes
and the ‘counterfactual’ ones we predict. We then fit a decision tree with the
“treatment-control difference” as the outcome variable to learn the sub-groups.
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Analogous to our approach in the parametric method, we eliminate sub-groups
which do not demonstrate ‘similar’ average “treatment-control differences” in the
training and validation datasets.
Thus, in both the parametric and non-parametric approaches, the results of the
first study is a set of sub-groups with observed heterogeneous ‘treatment-control’
differences that are not due to noise.
We then move on to the testing stage in Study 2, which is an experimental setting.
We ‘transport’ the partitioning rules learned in Study 1 as a priori hypotheses, and
classify Study 2 units based on their co-variates into these proposed sub-groups.
We now use the exogenous variation in treatment that the experimental setting
affords us to test for the hypothesized causal relationships in the sub-groups,
allowing testing of our proposed hypotheses from Study 1.
1.1 Generalizibility of inferences
In our setup, we are essentially transporting causal hypotheses from one setting
(observational) to another (experimental). There is a large body of work which has
been done in the space of generalizing/transporting inferences across different
settings [Cole and Stuart (2010); Tipton (2013)]. The key challenge in general-
izing/transporting causal inferences from one setting to specified targets is the
difference in distributions of baseline covariates between participants in the set-
tings. While a sound experimental design is the best bet in dealing with these
challenges, studies have proposed statistical approaches to deal with them. In
Pearl et al. (2014), the authors explicitly lay out graph-based criterion to deter-
mine when transportability is feasible, and when it is, to identify what experi-
mental and observational findings need be obtained and combined from the two
populations to ensure bias-free transport. In our setting, we ‘transport’ hypothe-
ses from an observational setting to an experimental setting, with the explicit
assumption about overlap in distributions of covariates.
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To our knowledge, this is the first study that proposes a novel two-study ap-
proach towards estimating heterogeneity in treatment effects. In exploiting the
‘largeness’ (despite potential unobserved confounding) of the observational data,
our approach better informs heterogeneity estimation in the experimental dataset
by proposing noise-free/stable a priori hypotheses, a feature we did not see in
other studies. This is in contrast to the dominant body of work in the machine
learning literature, which does the estimation in an experimental or observational
(with a no unobserved confounding assumption) settings, and are often under-
powered in empirical settings to rule out noise. We also compare our approach
to causal trees [Athey and Imbens (2016)] and find that our method out-performs
that method at identifying stable heterogeneous treatment effect sub-groups.
The rest of the paper is structured as follows. We describe the two-study para-
metric and non-parametric approaches in Section 2, and describe how we apply
the approach to patient claims data in Section 3. We lay out the empirical prob-
lem setup in Section 4, and define how we compare our method’s performance to
existing methods for estimating heterogeneity in Section 5. In Section 6, we sum-
marize the empirical results, and we discuss the implications and ongoing work
in Section 7. We conclude in Section 8.
2 Method
2.1 Study 1A: Proposing sub-groups using observational data -
parametric approach
As described earlier, one key aspect of observational data in a number of applied
policy settings is their relatively large sample size, and in Study 1, our aim is
to learn plausibly heterogeneous treatment effect sub-groups where the different
sized associations (magnitudes of the treatment-control difference) are not due to
noise. We use a sample-splitting approach to identify the noise-free sub-groups
- we split the data into ‘training’ and ’validation’ sets, and adopt a model-based
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recursive partitioning approach proposed by Zeileis et al. (2008) and Seibold et al.
(2016) to first learn the sub-groups on the ‘training’ set. We then use the ‘valida-
tion’ set to identify those sub-groups where the effect persists which we will call
“stable” heterogeneous sub-groups. We emphasize that Study 1 is a hypothesis-
generation stage - owing to the potential presence of confounding, we do not claim
the identified sub-groups are causal, and all references to treatment effects in this
section imply only potential causality which needs to be tested further.
2.1.1 Generate sub-groups using model-based recursive partitioning
As a first step, we specify a parametric model to estimate the relationship between
the treatment and outcome variables. We start with a base linear regression model
describing the conditional distribution of the outcome, denoted by Y , as a function
of “treatment”, denoted by a binary or continuous treatment variable (with linear
dose response assumption) A, and other co-variates, X˜:
Y = β0 + β1A+ β˜3X˜ +  (1)
While there may be heterogeneous sub-groups that differ in their treatment
effects, β1 here only reflects the average treatment effect. We describe sub-groups
as a partition {Bb}(b = 1, . . . , B) of all units in the sample i = 1, . . . , N . Here the
partition {Bb} is defined by J partitioning variables Z = (Z1, Z2, . . . , ZJ) ∈ Z.
These partitioning variables are characteristics of our units that we posit would
determine sub-groups with heterogeneous response to treatment. Without any a
priori knowledge about the partitions, we want to estimate the functions β0(z) and
β1(z) using model-based recursive partitioning as applied in Seibold et al. (2016).
The main idea here is to detect parameter instabilities - non-constant intercepts
(β0) and ‘treatment effects’ (captured by β1) - in the specified model by evaluating
the partial score functions with respect to β0 and β1:
ψβ0((Y,A,X), ϑ) =
δΨ((Y,A,X), ϑ)
δβ0
and
ψβ1((Y,A,X), ϑ) =
δΨ((Y,A,X), ϑ)
δβ1
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Here ϑ denotes the model parameters. If the model parameters are constant
and do not depend on the partitioning variables, then the partial score functions
ψβ0((Y,A,X), ϑ) and ψβ1((Y,A,X), ϑ) are independent of Z. Consequently, param-
eter instability corresponds to a correlation between either of the partial score
functions and at least one of the partitioning variables. In order to formally detect
deviations from independence between the partial score functions and the parti-
tioning variables, model-based recursive partitioning utilizes independence tests.
If we can reject at least one of the 2 × J null hypotheses for the pooled model at
a pre-specified nominal level, model-based recursive partitioning selects the par-
titioning variable Zj associated with the highest correlation to any of the partial
score functions. On finding an optimal cut-point Zj∗ < µ using a suitable criterion,
we split the sample into two subgroups according Zj∗ < µ. For both subgroups, we
estimate two separate models with parameters, ϑˆ(1) and ϑˆ(2) respectively, obtain
the corresponding partial score functions, and test the independence hypotheses.
If we find deviations from independence, we in turn estimate a cut-point in the
most highly associated partitioning variable, and split again. The procedure of
testing independence of partial score functions and partitioning variables is re-
peated recursively until deviations from independence can no longer be detected
(or based on other tuning parameters, such as minimum cluster size, to ensure
that our sub-groups are large enough for testing stability of the associations in
second study).
2.1.2 Validation set to rule out ‘noisy sub-groups’
Arguably, several different criteria could be used to classify learned sub-groups as
stable or noisy, and the choice may be application-dependent. One potential way
could be to compare the coefficient estimates in the sub-groups in the training
and validation sets, and define as stable those clusters which have similar esti-
mates across the two sets. Alternatively, some contexts might be less concerned
with matching the magnitude of the estimates in the two sets, and more with pre-
serving the rank-order of the estimates across the sets. In our study, we apply
the partitioning rules learned from running the recursive partitioning algorithm
on the ‘training set’ to data in the ‘validation’ set, and estimate the β1,val(n) value
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for each resulting sub-group (denoted by n) in the validation set. We then com-
pare these estimates to the β1,train(n) estimates for that same sub-group we learnt
using the training data. We define ‘stable high-impact’ sub-groups as sub-groups
(denoted by n) for which β1,train(n) and β1,val(n) are both significantly different from
zero at the 0.05 level and are in the same direction and fail to reject the null when
we test if the difference β1,train(n) − β1,val(n) is significantly different from zero at
the 0.05 level.
2.2 Study 1B: Proposing sub-groups using observational data -
Non-parametric approach
One of the limitations of the discussed approach in section above is that it re-
lies extensively on a particular parametric model specification (Equation 1). In
a number of settings, there is reason to doubt whether the parametric model is
valid. Further, in settings with a large co-variate space or in continuous treatment
cases (linear dose response assumption needed), a simple parametric model as we
use can be problematic. As the sub-group identification builds off on the spec-
ified model, the parametric approach also assumes similar treatment-outcome
parametric relationships across sub-groups, which need not necessarily be true.
Moreover, a non-parametric model to estimate the treatment-control differences
could more exhaustively capture the the effect of observed confounders within the
sub-groups (as in this case, we are including all the co-variates to predict the
‘counterfactual’ outcomes), compared to the linear model used in Equation 1. To
address these concerns, we propose a non-parametric approach for learning and
validating the sub-groups in Study 1.
We relax the parametric model assumption in Study 1 to estimate the sub-groups
non-parametrically using the following approach. Our objective from this step
is to learn “stable” sub-groups . In addition to addressing concerns over model
specification, this approach does more to address potential observed confound-
ing in Study 1 sub-group identification. This method is a plug-in version of the
‘counterfactual’ and sub-group estimation strategy adopted in van der Laan and
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Luedtke (2014) and Foster et al. (2011).
We devise the non-parametric learning & estimation as a three-step procedure.
We state these three steps below, and cover them in detail in Section 2.3.
1. We non-parametrically estimate the “counterfactual” outcome for each indi-
vidual in our sample and then use that to estimate the treatment-control
difference (TCD) for each individual.
2. We then partition individuals into sub-groups based on their TCD.
3. Finally, we validate the ‘stability’ of the learnt sub-groups.
2.3 Defining the Treatment-Control Difference parameter
In a dichotomous treatment setting (A ∈ {0, 1}), for each unit in the ‘training’ data,
we define the conditional treatment effect γ as:
γ(X) = E(Y 1 − Y 0|X)
=⇒ γ(X) = E(Y 1|X)− E(Y 0|X)
Assuming conditional exogeneity/randomization [E(Y a|X) = E(Y a|X,A = a)], we
have:
=⇒ γ(X) = E(Y 1|X,A = 1)− E(Y 0|X,A = 0)
By consistency [Y = AY 1 + (1−A)Y 0], we have:
=⇒ γ(X) = E(Y |X,A = 1)− E(Y |X,A = 0)
However, in an observational setting, the first assumption (unconfoundedness) is
a problematic one. γ(X) in a setting where this assumption does not hold is not
the conditional treatment effect parameter, and any estimation of the parameter
should not be interpreted thus. For the purpose of hypothesis generation, how-
ever, which is the objective of our Study 1, we call γ(X) the treatment-control
difference (TCD).
We follow these steps (depicted in Figure 2.3):
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1. We randomly split our Study 1 observational data into three equally sized
‘training’, ‘prediction’ and ‘validation’ sets.
2. Treatment-Control Difference (TCD): On ‘training’ data, we estimate E(Y |X,A =
1) and E(Y |X,A = 0) separately on the treatment and control groups respec-
tively to get the following estimators:
µˆ1(X) = Eˆ(Y |X,A = 1)
µˆ0(X) = Eˆ(Y |X,A = 0)
For every treatment unit i, we have:
γˆ(Xi) = y1(Xi)− µˆ0(Xi)
where y1(Xi) is the observed outcome of the treatment unit i.
For every control unit j, we have:
γˆ(Xj) = µˆ1(Xj)− y0(Xj)
where y0(Xj) is the observed outcome of the control unit.
3. Estimation of “counterfactual” outcomes on training data: We estimate
µ0(X) and µ1(X) on the training set to give us the following estimates: µˆ0,trn(X)
and µˆ1,trn(X).
We estimate each of the estimates by running two random forest models
(one on control units, and one on treatment units) on the training subset
of the observational data. We tune the hyper-parameters of these random
forests (node size, tree depth, number of variables) using a cross-validation
approach.
4. Estimation of “counter-factual” outcomes on validation data: Similarly,
we run two random forest models to estimate µ0(X) and µ1(X) on the valida-
tion set to give us µˆ0,val(X), and µˆ1,val(X).
5. Estimation of TCD: Using the above, we calculate the treatment-control dif-
ference for every unit i in the training set (Ntrn) by using this formula:
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For every treatment unit, we have:
γˆtrn(Xi) = y(Xi)− µˆ0,trn(Xi)
where y(Xi) is the observed outcome of the treatment unit.
For every control unit j, we have:
γˆtrn(Xj) = µˆ1,trn(Xj)− y(Xj)
where y(Xj) is the observed outcome of the control unit.
We do the same for every unit in the validation set (Nval). Treatment unit i:
γˆval(Xi) = y(Xi)− µˆ0,val(Xi)
Control unit j:
γˆval(Xj) = µˆ1,val(Xj)− y(Xj)
6. Learning sub-groups: We now want to learn the partitioning rules to be able
to apply them to the Study 2 experimental setting. We learn them by fitting
a decision tree (CART) to the ‘prediction’ data. Here we use with γˆpred(X) as
the outcome variable for the CART and the co-variates X as the partitioning
variables, where γˆpred(X) is predicted using the forest models we fit on the
‘training’ set. We use the variable vector X to construct the tree. We use a
cross-validation approach to avoid over-fitting. Thus, each of the terminal
nodes n in the learnt partitioning tree is a proposed sub-group, with γˆpred(n)
as the average treatment-control difference for each sub-group n.
γˆpred(n) =
∑Npred
i=1 1i∈nγˆpred(Xi)∑Npred
i=1 1i∈n
7. We now apply the partitioning rules learned in Step 6 to the validation set
(note: we have already estimated the TCD γˆval(X) for each unit of the ’valida-
tion set’ in Step 5). Thus, for each of the terminal nodes n in the validation
set, we can then calculate the average γˆval(n)
γˆval(n) =
∑Nval
j=1 1j∈nγˆval(Xj)∑Nval
j=1 1j∈n
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8. Identifying ‘stable’ sub-groups: Analogous to the parametric setting in Sec-
tion 2.1.1, we define a sub-group n as a “stable” proposed high-impact group
if γˆpred(n) and γˆval(n) are both significantly different from zero at the 0.05 level
and are in the same direction; and if we fail to reject the null when we test if
the difference γˆpred(n)− γˆval(n) is significantly different from zero at the 0.05
level. We define a sub-group n as a “stable” proposed low-impact group if we
fail to reject the null that γˆpred(n) and γˆval(n) are both significantly different
from zero at the 0.05 level. We use boostrapping to estimate the standard
errors of the mean TCD within each learnt subgroup
OBSERVATIONAL DATA
Learn
γˆtrn(X)
Predict
γˆpred(X)
Fit tree based on γˆpred(X)
to learn sub-groups
Calculate mean γˆpred(n)
in each sub-group n
Apply learnt tree
rules to assign units
to sub-groups
Learn
γˆval(X)
Calculate mean γˆval(n)
in each sub-group n
Figure 1: Non-parametric learning and validation of sub-groups
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2.4 Study 2: Testing sub-groups in experimental setting
As noted earlier, in Study 1 we cannot conclude causality because of the presence
of potential unobserved confounding in the observational data. This brings us
to our Study 2 which is run in an experimental setting. We classify data (of
a similar co-variate structure as the observational data from Study 1) from a
setting with exogenous variation (experimental or quasi-experimental setup) into
the sub-groups we learned and validated in Study 1. We then estimate the causal
responses to treatment for each of these sub-groups. Depending on the nature
of the outcome variable and the experimental setting, we can apply appropriate
outcome modeling approaches based on Study 2 design - simple regression models
for a randomized control trial or traditional difference-in-differences models or
doubly robust semi-parametric estimation models - to estimate the effects.
3 Application to Patient Claims Data
As a proof of concept, we apply the two-study approach to learn and test sub-
groups with heterogeneous effects of a switch to high-deductible health plans
(HDHPs) on use of outpatient care by 18-64 year old high-cholesterol patients.
There has been extensive research on how high-deductible health plans (HDHPs)
impact use of healthcare. In Haviland et al. (2016), the authors find that health-
care spending is reduced for enrollees in firms offering consumer directed health
plans (CDHPs), and the reduction was driven by spending decreases in outpa-
tient care and pharmaceuticals. In Brot-Goldberg et al. (2017), the authors find
that enrollees at a firm that switched from an insurance plan that provided free
health care to a high-deductible plan, reduced quantities across the spectrum
of health care services, including potentially valuable care (e.g., preventive ser-
vices) and potentially wasteful care (e.g., imaging services). They also find that
these spending reductions came in large part from well-off and predictably sick
consumers facing reasonably low yearly out-of-pocket maximums. In Huckfeldt
et al. (2015), the authors investigate how CDHP enrollees change use of phar-
maceuticals for chronic diseases, and find reduction in utilization, regardless of
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whether the pharmaceuticals were exempt from the deductible. While several
studies have focused on the average effect of a switch to HDHPs on use of care,
understanding how the response differs across different patient sub-groups is an
important policy question. There might be sub-groups of patients who might be
harmed by enrollment in CDHPs due to forgoing needed care, or sub-groups for
whom a CDHP switch might not a significant impact on health use. To the best of
our knowledge, any assessment of heterogeneous responses in these studies was
done ex-post, as opposed to testing for any specific a priori hypotheses.The prob-
lem gets understandably compounded by the largeness of the co-variate space
(clinical and demographic characteristics) and and lack of theory for fine-grained
sub-groups. Statistical machine learning techniques can be appropriate in situa-
tions such as this.
In our study, we use patient claims data from The Truven Health MarketScan R©
Research Databases from two years (2010-2011). The MarketScan databases
reflect the health-care experience of employees and dependents covered by the
health benefit programs of large employers. These claims data are collected from
approximately 100 different insurance companies. These data represent the med-
ical experience of insured employees and their dependents for active employees,
early retirees, COBRA continuees and Medicare-eligible retirees with employer-
provided Medicare Supplemental plans. They capture person-specific clinical uti-
lization, expenditures, and enrollment across inpatient, outpatient, prescription
drug, and carve-out services.
We exploit two features of this dataset which allow us to apply our two-study
approach. First, one of the employers in our two-year time period switches com-
pletely to high-deductible health insurance plans in the second year (2012) from
a suite of mostly low-deductible health plan offerings in the first year (2011). This
lays the premise for Study 2 by providing us a quasi-experimental setup where
the switch to a high-deductible plan is an exogenous cost shock from an enrollee’s
perspective. Our sample has (N ∼ 8500) enrollees who meet our sample inclusion
criteria in the full-replacement firm. Second, our first year of data (2011) provides
Sub-groups with Heterogeneous Treatment Effects
us the framework for Study 1, as we observe enrollees (N ∼ 130,000) meeting
the sample inclusion criteria in a diversity of health insurance plans offered by
multiple employers, with considerable variation in costs. We use this variation to
learn the heterogeneous effect sub-groups.
4 Problem Setup
Figure 2 depicts the data setup for the two-study approach. Let S ∈ {1, 2} indicate
the study state (1 or 2), where S = 1 is Study 1 (observational setup), and S = 2
be the Study 2 (experimental setup). Let As indicate value of treatment variable
(continuous) in any study s.
In this dataset, as we have a fixed cost shock (for the full-replacement employer)
in Study 2, we re-define the treatment variable to assume a discrete value. We
define B as the indicator for treatment, where t is the threshold value of the cost
variable. Then,
B =

1 if A2 ≥ t ≥ A1
0 if A1, A2 < t
−1 if otherwise
Here, B = 1 indicates enrollees in the full-replacement firm which are subject to
the exogenous cost-shock, while B = 0 indicates enrollees in firms which do not
see any change in the cost shock over the two years (enrollees in these firms serve
as ‘controls’ for our ‘treatment’ firm enrollees). B = −1 for enrollees in S = 1.
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2011 2012
S = 1
S = 2
Observational Data Enrollees B = -1
Enrollees in ‘Control’ Firms B = 0
Enrollees in Full Replacement ‘Treatment’ Firm B = 1
Figure 2: Two-Study Data Setup
We use Study 1 (S = 1) to learn ν = f(X), which indicates learned sub-groups
from Study 1 and is defined as a function of the co-variates (partitioning variables
X).
For Study 2 (S = 2), we define the Conditional Average Treatment Effect (CATE)
parameter to be estimated in each of the sub-groups ν as:
CATE = E[Y b=12 − Y b=02 | ν, S = 2] = γ(ν) (2)
Under the following assumptions:
• Ignorability
B ⊥⊥ Y b2 | ν, S = 2
• Consistency
Y2 = BY
1
2 + (1−B)Y 02
We use Equation 2 :
γ(ν) = E[Y b=12 | ν, S = 2]− E[Y b=02 | ν, S = 2]
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Using ignorability, this is equal to:
γ(ν) = E[Y b=12 | ν, S = 2, B = 1]− E[Y b=02 | ν, S = 2, B = 0]
Then, using consistency, we have:
γ(ν) = E[Y2 | ν, S = 2, B = 1]− E[Y2 | ν, S = 2, B = 0] (3)
4.1 Sample Selection
For our study, we focus our analysis on 18-64 year old adults who have a chronic
condition - high cholesterol (hyperlipidemia). For patients with a chronic condi-
tion, there is a concern that reduction in health care use could be sub-optimal
and welfare reducing. A sustained engagement with the health-care provider -
captured by outpatient visits - is presumed to be optimal for this patient group.
Further, having a more homogeneous study population - those with this particu-
lar chronic condition - may reduce issues of selection into plans. For our sample,
we select 18-64 year old enrollees (or spouse) who
• are continuously enrolled through the same employer for 24 months (2011-
12), and
• have at least one claim in the outpatient services file for the first six months
of 2011, with any of the four diagnostic codes classified for hyperlipidemia.
We note that from an empirical perspective, as we have access to claims data
alone, for constructing enrollees’ clinical profiles, we are limited to enrollees that
have at least one claim in the outpatient services.
4.2 Study 1A: Learning sub-groups - parametric approach
4.2.1 Defining ‘Outcome’ and ‘Treatment’ measures
We estimate the heterogeneous effects of a switch to a high-deductible health in-
surance plan on patients’ use of care. In our setting, we define care to specifically
mean outpatient (OP) care, as measured by number of OP visits. We define the
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treatment variable as the cost exposure enrollees face for an outpatient visit. We
posit that the effect of the switch to a high-deductible plan is through exposure
to the out-of-pocket cost shock that enrollees face due to the switch. To define
the out-of-pocket cost exposure, we construct a health-plan level measure which
is similar to an actuarial value for OP visits in particular. This is needed as us-
ing the raw out-of-pocket costs that patients face (sum of copay/coinsurance and
deductible) across visits does not capture the non-linearity in prices patients face
over time (due to plans’ cost-sharing features) and are also endogenous to the
enrollee. Moreover for comparing across plans, any such measure also needs to
account for heterogeneity in plans’ enrollees - to mitigate the issue of enrollees
selecting into plans based on information private to the enrollees. We define the
measure in the appendix. We note that our treatment variable (cost exposure) is
a continuous variable, and we assume a linear dose response relationship in the
parametric model.
Our pooled model is the following simple linear regression model:
log(OP Visits)i = β0 + β1 × Cost Exposurei + i (4)
4.2.2 Partitioning Variables
In the case of our study, we have patient demographic features - age and gender
- and a summary of clinical features we obtain from the inpatient admissions,
outpatient services, and outpatient drug files. We use patients’ 2011 claims data
to construct their clinical and demographic profiles. Below are the clinical features
we consider in the model-based recursive partitioning algorithm:
• Number of unique therapeutic drug classes (range of values)
• Indicator of whether patient was ever admitted to the hospital in the time-
period of the observational data
• Indicators of whether patient had an OP service claim ever for each of the top
ten most-frequently-occurring ‘Major Diagnostic Categories’ (MDCs)
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• Indicators of whether patient had an OP drug claim ever for each of the top
twenty most-frequently-occurring therapeutic drug classes
We also define a categorical variable that categorizes patients into three bins
based on their overall health-care expenses (total payments inclusive of out-of-
pocket payments and payments made by insurer). Patients with total payments
less than 2500 USD were in the ‘low strata’, with payments between 2500-6000
USD were in ‘medium strata’, and those with payments higher than 6000 USD
were in the ‘high strata’. We note that feature selection is a complex task open
to subjectivity. We employ the following procedure to inform the feature selec-
tion procedure. We ran three combinations of the aforementioned partitioning
variables (in increasing levels of granularity) with varying levels of the minimum
cluster size (1000,1500,2000, 3000), and used a cross-validation approach to se-
lect the feature set and cluster size combination using ‘validation’ set MSE/AIC
as the criterion.
4.2.3 Model-based Recursive Partitioning
As described in Section 2.1, we apply the model-based recursive partitioning al-
gorithm to the 2011 claims data for patients in our sample. We exclude patients
from the full-replacement firm while forming the groups, and also exclude pa-
tients from three ‘comparison’ firms - these are firms for which we do not see any
change in the nature of plans (similarly priced) offered over 2010-11.
4.3 Study 1B: Learning sub-groups - non-parametric approach
We now use the approach as described in Section 2.2. We use the same 2011
claims data and the inclusion criteria and the partitioning variables as described
in Sections 4.1 and 4.2. A major difference between the two approaches is how
we define our treatment variable. In the parametric approach, the weighted cost-
exposure was considered as a continuous treatment variable, with a linear dose-
response assumption. For our non-parametric method, we need to explicitly de-
fine our treatment and control individuals in Study 1 on which we run our random
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Figure 3: Cost Exposure Shock in Study 2
forest models to estimate the predicted outcomes with and without treatment. As
we are interested in estimating the causal effect of a cost-shock owing to switch
to HDHPs in Study 2, we use the Study 2 setup to define these groups. From
Study 2, we learn that the average change in cost-exposure that results from a
switch to a HDHP is $45 (see Figure 4.3. Based on that metric and on the nature
of the data-set (distribution of costs, sample size), we define “control” individuals
in Study 1 with plan-level weighted out-of-pocket cost exposure between $0-15
(Nc = 55, 146), and “treatment” individuals with plan-level weighted out-of-pocket
cost exposure between $40-70 (Nt = 55, 542).
4.4 Study 2: Testing for causality
For Study 2, we focus our analysis on enrollees in our sample from the full-
replacement firm and from one ‘comparison’ firm in our data. These ‘comparison’
firm is one which has the same (similarly-priced) plans on offer in both the years.
Including enrollees from control firm in the Study 2 analysis helps us to estimate
changes in use of care attributed to the switch, as opposed to those over time.
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We classify the enrollees in these firms based on the partitioning rules learned
from Study 1 using their 2011 claims data, and then run the following difference-
in-differences outcome model in each of the sub-groups on their 2011 and 2012
use of care. In Study 2, we adopt the same approach for the groups learnt from
the parametric and the non-parametric approaches. We follow a negative binomial
regression model.
yit = β0 + β1Postt × Treatmenti + β2Postt + β3Treatmenti + it1 (5)
In Equation 5, Post = 1 in the second year (2012) and = 0 in 2011; Treatment= 1
for enrollees in the full-replacement firm, and = 0 for enrollees in comparison
firms. The parameter β1 captures the difference-in-differences estimate of the
effect of the switch to the high-deductible plan in each of the sub-groups.
5 Comparison with other methods of estimating treat-
ment effect heterogeneity
We also evaluate how our two-study approach performs in comparison with the
”causal tree” based method described in Athey and Imbens (2016). We note that
this method uses post-experiment data alone to estimate heterogeneity, while we
use observational data along with experimental data. We train the “causal” tree
on a split ‘training’ set from the experimental dataset, using the cross-validation
approach as described in the study. We estimate the effects on the ‘validation’ set
from the experimental dataset, and compare the group estimates from the ‘train-
ing’ and ’estimation’ sets to determine which of the sub-groups hold up across
them.
1We cluster standard errors at enrollee level
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6 Results
6.1 Findings from Study 1 Parametric approach to 2011 claims
data
We find 9 proposed high-impact sub-groups with persistent effects using the
cross-validated model-based recursive partitioning approach. Figure 4 depicts
the training and validation estimates (with 95 % CI) of percent change in use of
care for a $45 increase in cost exposure for the sub-groups.
Figure 4: Comparison of training and validation estimates in Study 1
6.1.1 Cluster Example
Below is an example of a proposed “high-impact” sub-group identified in Study 1.
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Potential ’High-impact’ group
Enrollees > 49 yo, with ≤ 6 unique drug classe prescriptions, ‘medium-strata’ of
enrollees based on overall costs, & claim not for “Musculoskeletal System &
Connective Tissue” diseases,
a $45 ↑ in cost exposure associated with 13.5% ↓ in OP care use
6.2 Findings from Study 1 Non-Parametric approach to 2011
claims data
We find 12 ‘high-impact’ patient sub-groups with persistent effects using the
cross-validated random forest approach described in Section 2.2. Figure 5 depicts
the training and validation estimates (with 95% CI) of the proposed treatment-
control difference of the cost shock.
Figure 5: Comparison of Study 1 non-parametric training & validation estimates
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6.2.1 Cluster Example from Non-parametric implementation
Below is an of the proposed “stable” sub-group identified using the non-parametric
approach in Study 1.
Potential ’High-impact’ sub-group
Enrollees > 47 yo, ≥ 3 unique drug class prescriptions, ‘medium-strata’ wrt
overall-cost, claim for “Endocrine, Nutritional & Metabolic” diseases & not for
‘Ear, Nose, Mouth & Throat” diseases,
a ∼$45 ↑ in cost exposure associated with 15% ↓ in OP care use
6.3 Findings from Study 2 approach to experimental setting
Figure 4.3 depicts the exogenous cost-exposure shock associated with the full-
replacement firm’s switch from its suite of low-deductible health offerings to high-
deductible health plans. The histogram reflects the distribution of the cost expo-
sure variable in the observational data, and we note that the cost exposure shock
is of a significant magnitude ( 100%) of the pre-switch year cost exposure.
Table 1 shows how our hypothesized ‘high-impact’ sub-groups from the two ap-
proaches ‘respond’ to the cost-shock due to the switch to the high-deductible plan
in Study 2. We note that 4 of the 9 sub-groups we proposed to be ’high-impact’ in
the parametric setup were demonstrably ‘high-impact’ in the experimental setting.
Of the 12 sub-groups that we proposed to be ’high-impact’ in the non-parametric
setup, 7 were demonstrably ‘high-impact’ in the experimental setting.
In Figure 6, we plot the β1 estimates from Equation 5 with the 95% confidence
interval. Cluster 0 (leftmost on the panels) is the estimate (and 95%CI) of β1 for the
pooled data, while the remaining estimates are for clusters we hypothesized to be
‘high-impact’ from Study 1. We note that the point estimates for our hypothesized
sub-groups were on average ‘more negative’ compared to the pooled point estimate
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(despite wider confidence intervals). The confidence intervals are wider for the
sub-group estimates due to their relative smaller sample sizes compared to the
pooled sample.
Classification Clusters
Parametric Method Confirmed in Study 2 4/9
Fail to Reject Null 5/9
Non-parametric Method Confirmed in Study 2 7/12
Fail to Reject Null 5/12
Table 1: Testing hypotheses in experimental setting (Study 2)
6.4 Findings from comparison with causal trees
We implemented the causal tree approach in Athey and Imbens (2016). We used
only Study 2 data for this method. It identified five sub-groups on ‘training’ set
(see Figure 7). None of the groups hold on the validation set, however.
7 Discussion
Our results demonstrate that when going into an experimental study for estimat-
ing heterogeneity in treatment effects, a Study 1 approach as a precursor could
be an informative step to address power limitations associated with small sample
sizes. Observational data alone is limited by concerns of endogeneity which make
causal inference difficult in the absence of assumptions of unobserved confound-
ing. At the same time, the ‘largeness’ that observational data usually affords
researchers can be exploited to generate “noise-free” or “stable” hypotheses re-
garding heterogeneous treatment effects going into a subsequent experiment.
In our results, we note that 4 of the 9 proposed ‘high impact’ sub-groups in
the parametric approach (and 7/12 in non-parametric) were tested to be causally
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Figure 6: Causal Estimates from Study 2 - Parametric and non-parametric ap-
proaches
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Figure 7: Causal tree approach from Athey and Imbens (2016) on Study 2 data
high-impact. These results both are informative about heterogeneity and about
the nature and direction of confounding across the identified sub-groups. At the
same time, the wide confidence intervals indicate that we might still be handi-
capped by sample size issues, and we are working on ‘tuning’ the hyper-parameters
in Study 1 (higher minimum cluster size for instance) to evaluate how that would
affect our Study 2 estimates. When we use the non-parametric approach, we are
able to lean 5 ‘high-impact’ sub-groups, of which 4 hold with marginal signifi-
cance.
7.1 Explore nature of confounding
The results where some groups stood the causality test while some did not, in-
dicate the need to assess the role that the direction of confounding plays in
driving this. It serves to explicitly note under what conditions of confounding
(same/different across groups) would hypotheses be expected to hold. This has
implications based on the context in which this method can be applied. For ex-
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ample, in settings where we are just concerned with the ranking of effects across
sub-groups and it can be assumed that all sub-groups are affected similarly by
confounding, this method would find more salience than settings with differential
confounding.
7.2 Application to other datasets
At present, we have applied this two-study approach to a setup with one full-
replacement employer providing us the exogenous variation for our Study 2 set-
ting. We are actively searching for data-sets which would fit this two-study mould.
As examples, we are searching for datasets which could serve as Study 1 datasets
for the Oregon Health Insurance Experiment or RAND health insurance experi-
ment dataset.
7.3 Continuous Treatment Regimes
In the application to claims data, our treatment variable is the cost exposure,
which is a continuous variable (notably in Study 1, with the distribution of costs
across plans), while it is a discrete cost shock in Study 2 (owing to the cost shock
δ happening at the plan level). To account for this, we modify our γ parameter to
the following:
γˆ(X) = E(Y |X,A = a+ δ)− E(Y |X,A = a)
We are interested in estimating the counterfactual distribution for each of our
units where δ is the cost shock (fixed as defined by Study 2) and a is the level of
observed cost-exposure in Study 1.
8 Conclusion
When approaching an exogenous treatment intervention with an interest in het-
erogeneous effects, we demonstrate it is helpful to consider carrying out a Study
1 to inform it. Study 1 can use statistical machine learning methods to identify
groups that may have heterogeneous treatment effects. These sub-group specific
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treatment effects may be biased due to confounding, but are not due to noise.
Study 2 can then be used to determine which of the hypothesized effects are
causal. To our knowledge, this is the first study that proposed using observa-
tional data in conjunction with experimental data in a two-study approach to
estimate heterogeneity.
As the results demonstrate, further exploration of the direction of confounding
in both the ‘low impact’ and ‘high impact’ sub-groups is called for. As future
work, we also plan to incorporate medical and clinical review for interpretability
of these clusters and to better understand mechanisms for heterogeneous causal
effects based on these partitioning variables. Methodologically, future work will
involve applying the proposed non-parametric approach to sub-group estimation
and explorations of applying this framework to dynamic treatment regimes.
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